MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-06-2026
BeiGene, Ltd. DSO Ratio 2011-2026 | BGNE
Annual DSO Ratio BeiGene, Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.6 | 49.5 | 39.4 | 84.6 | 84.3 | 77.6 | 62.1 | 97.2 | 45.1 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 97.2 | 39.4 | 65.8 |
Quarterly DSO Ratio BeiGene, Ltd.
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.3 | 52.8 | 51.6 | 56.9 | - | 50 | 47.4 | 48.1 | - | 35.5 | 46.7 | 49.2 | - | 42.5 | 48.5 | 100 | - | 45 | 48 | 10.9 | 55.1 | 60.5 | 84 | 115 | 114 | 129 | 26.6 | 65.6 | 63.9 | 69.1 | 71 | 98.8 | 148 | 12.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 148 | 10.9 | 63.3 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
2.94 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Exelixis
EXEL
|
43.4 | $ 48.16 | 4.22 % | $ 13.1 B | USA |
 |
Fortress Biotech
FBIO
|
115 | $ 2.39 | -0.42 % | $ 66.7 M | USA |
 |
Compugen Ltd.
CGEN
|
60.8 | $ 2.9 | 1.4 % | $ 271 M |  Israel |
 |
ACADIA Pharmaceuticals
ACAD
|
37.5 | $ 22.4 | -0.71 % | $ 3.71 B | USA |
 |
Genmab A/S
GMAB
|
97.9 | $ 26.43 | -2.33 % | $ 1.71 B |  Danmark |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
99.7 | $ 3.14 | - | $ 653 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 3.51 | -0.85 % | $ 5.78 M | Israel |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
Gilead Sciences
GILD
|
57.8 | $ 131.33 | -2.04 % | $ 163 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
106 | $ 21.17 | 2.47 % | $ 2.69 B | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 54.83 | 4.6 % | $ 4.93 B |  Schweiz |
 |
Autolus Therapeutics plc
AUTL
|
58.2 | $ 1.57 | -2.48 % | $ 418 M | Britain |